for-phone-onlyfor-tablet-portrait-upfor-tablet-landscape-upfor-desktop-upfor-wide-desktop-up

Imv Inc

IMV.TO

Latest Trade

--

Change

--(--)

Today's Range

--

 - 

--

52 Week Range

--

 - 

--

As of on the Toronto Stock Exchange ∙ Minimum 15 minute delay

Pricing

Previous Close
--
Open
--
Volume
--
3M AVG Volume
0.87
Today's High
--
Today's Low
--
52 Week High
--
52 Week Low
--
Shares Out (MIL)
50.63
Market Cap (MIL)
263.18
Forward P/E
-10.16
Dividend (Yield %)
--

Latest Developments

More

IMV's Updated Clinical Data From Phase 2 Spirel Study Evaluating DPX-Survivac As A Combination Therapy In r/r DLBCL

IMV Qtrly Diluted Loss Per Share C$0.16

IMV Says QTRLY Loss Per Share $0.10

for-phone-onlyfor-tablet-portrait-upfor-tablet-landscape-upfor-desktop-upfor-wide-desktop-up

About Imv Inc

IMV Inc. is a clinical-stage biopharmaceutical company focused on immunotherapy in oncology. The Company’s drug delivery platform (DPX) enables the programming of immune cells in vivo. The Company’s lead candidate, DPX-Survivac, is a T cell-activating immunotherapy combining DPX with a specific tumor target: Survivin. DPX-Survivac is a monotherapy in ovarian cancer and in combination with Merck's Keytruda across multiple cancer indications.

Industry

Biotechnology & Drugs

Contact Info

130 Eileen Stubbs Ave Suite 19

+1.902.4921819

https://imv-inc.com/

Executive Leadership

Andrew J. Sheldon

Chairman of the Board

Frederic Ors

Chief Executive Officer, Director

Pierre Labbe

Chief Financial Officer

Joseph Sullivan

Senior Vice President - Business Development

Marc Jasmin

Senior Director, Director of Investor Relations

Key Stats

1.80 mean rating - 5 analysts
Sell
Hold
Buy
Revenue (MM, CAD)

2016

0.0K

2017

0.0K

2018

0.0K

2019(E)

0.0K
EPS (CAD)

2016

-0.288

2017

-0.320

2018

-0.500

2019(E)

-0.512
Price To Earnings (TTM)
--
Price To Sales (TTM)
464.99
Price To Book (MRQ)
17.98
Price To Cash Flow (TTM)
--
Total Debt To Equity (MRQ)
66.56
LT Debt To Equity (MRQ)
65.29
Return on Investment (TTM)
-116.46
Return on Equity (TTM)
-93.99

Latest News

Latest News

BRIEF-Immunovaccine Announces $12.5 Million Bought Deal Offering

* IMMUNOVACCINE INC - ENTERED INTO BOUGHT DEAL FINANCING AGREEMENT TO SELL 6.3 MILLION COMMON SHARES AT A PRICE OF $2.00 PER COMMON SHARE Source text for Eikon: Further company coverage:

BRIEF-Immunovaccine announces positive clinical data from its collaborative combination immunotherapy trial in advanced ovarian cancer

* IMMUNOVACCINE ANNOUNCES POSITIVE CLINICAL DATA FROM ITS COLLABORATIVE COMBINATION IMMUNOTHERAPY TRIAL IN ADVANCED OVARIAN CANCER

BRIEF-IMMUNOVACCINE AND LEIDOS EXPAND COLLABORATION TO DEVELOP MALARIA VACCINE CANDIDATES

* IMMUNOVACCINE AND LEIDOS EXPAND COLLABORATION TO DEVELOP MALARIA VACCINES FORMULATED IN DEPOVAX Source text for Eikon: Further company coverage:

BRIEF-Immunovaccine reports qtrly loss per share of ‍$0.02​

* Immunovaccine announces third quarter 2017 financial results

BRIEF-Immunovaccine announces regulatory clearance for Phase 2 clinical trial evaluating DPX-Survivac

* Immunovaccine announces regulatory clearance for Phase 2 clinical trial evaluating DPX-Survivac in combination with Merck's checkpoint inhibitor Pembrolizumab in DLBCL Source text for Eikon: Further company coverage:

BRIEF-Immunovaccine receives an extension to the maturity date of its $5m loan until 2020

* Immunovaccine receives an extension to the maturity date of its $5m loan until 2020

BRIEF-Immunovaccine announces achievement of milestones in collaboration with Zoetis to develop veterinary vaccines

* Immunovaccine announces achievement of milestones in collaboration with Zoetis to develop veterinary vaccines Source text for Eikon: Further company coverage:

BRIEF-Immunovaccine Q2 loss per share C$0.02

* Immunovaccine announces financial results for quarter ended June 30, 2017

BRIEF-Immunovaccine announces achievement in personalized cancer medicines

* Immunovaccine achieves breakthrough in support of developing personalized cancer immunotherapies

BRIEF-Immunovaccine announces $10 million bought deal offering

* Immunovaccine Inc says intends to use net proceeds of offering to advance company's various depovax™-based products clinical studies

BRIEF-Immunovaccine says to initiate mid-stage trial of its blood cancer drug

* Immunovaccine's lead immuno-oncology candidate to enter investigator-sponsored phase 2 clinical trial in DLBCL in combination with approved anti-PD-1 drug

BRIEF-Immunovaccine net loss, comprehensive loss of $2.4 mln for quarter ended March 31

* Immunovaccine announces financial results for quarter ended March 31, 2017

BRIEF-Immunovaccine announces positive year-long immunogenicity data from phase 1 clinical trial for respiratory syncytial virus vaccine candidate

* Immunovaccine announces positive year-long immunogenicity data from phase 1 clinical trial for respiratory syncytial virus vaccine candidate

BRIEF-Princess Margaret Cancer Center receives Health Canada clearance to begin investigator-sponsored phase 2 ovarian cancer study

* Princess Margaret Cancer Center receives Health Canada clearance to begin investigator-sponsored phase 2 ovarian cancer study evaluating immunovaccine's DPX-survivac with Merck's pembrolizumab

BRIEF-Immunovaccine presents preclinical research on novel monoclonal antibodies

* Immunovaccine Inc presents preclinical research at aacr 2017 on ability of novel monoclonal antibodies to boost efficacy of depovax(tm)-based cancer immunotherapy

BRIEF-Immunovaccine announces positive interim clinical data from Ovarian cancer study

* Immunovaccine announces positive interim clinical data from ovarian cancer study of DPX-survivac in combination with epacadostat

BRIEF-Immunovaccine says Princess Margaret Cancer Centre to conduct Phase 2 clinical trial to evaluate use of co, Merck's combination of immunotherapies

* Immunovaccine's lead immuno-oncology candidate to enter investigator-sponsored Phase 2 clinical trial in ovarian cancer in combination with approved anti-PD-1 drug

BRIEF-Immunovaccine appoints Pierre Labbe as CFO

* Immunovaccine appoints seasoned financial executive Pierre Labbe as CFO

Quote and financial data from Refinitiv. Fund performance data provided by Lipper. All quotes delayed a minimum of 15 minutes.

for-phone-onlyfor-tablet-portrait-upfor-tablet-landscape-upfor-desktop-upfor-wide-desktop-up